Navigation Links
New Report Defines Challenges for New Entrants in Key Rheumatology Markets
Date:4/7/2009

MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015

SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis, lupus, gout and psoriatic arthritis.

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted a thought exercise with four North American and four European rheumatologists. The purpose was to identify their "must have" branded and generic drugs for their real-world practices in the year 2015. This report outlines each panelist's "Fantasy Formulary," and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.

"It is essential that drug developers consider the entire rheumatology practice when establishing their strategies going forward," according to Dr. Jeffrey Berk, MedPredict's president and one of the report's authors. "One key insight from our research is that drugs which will be beneficial across multiple indications are going to have an easier time getting on formulary."

The report will answer the following questions:

  • What are these thought leaders' top ten choices for their rheumatology practice in 2015?
  • How do their choices differ by geography, and why?
  • How will the availability of biosimilars for substitution of first generation biologics impact the environment for new entrants?
  • What is the preferred anti-TNF drug, and why?
  • Where will new mechanistic approaches, such as Jak and Syk inhibitors, IL-17, anti-B-cell, and others fit in the rheumatologist's armamentarium?

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen, Amgen/Wyeth, Biogen Idec, Bristol-Myers Squibb, Can-Fite, Centocor, Centocor/Schering-Plough, Chelsea, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, J&J/Alza, Lilly, Medarex, Merck, Merck Serono/ZymoGenetics, Mitsubishi Tanabe, Neovacs, Nitec/SkyePharma, Novartis, Pozen/AstraZeneca, Rigel, Roche, Roche/Chugai, Roche/Genentech/Biogen Idec, Sanofi-Aventis, Savient, Takeda, UCB, Vertex, and Wyeth/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pain in the ICU report suggests comprehensive approach
2. Photos: Report Shows Youth Health Educators Reach More Poor Teens with a Message of Living Healthy Lives!
3. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
4. Hazardous Health Plans: Consumer Reports Investigation Finds Serious Gaps in Individual Health Insurance Policies
5. Consumer Reports Survey: Hands-On Therapies Among Top-Rated Treatments for Back Pain
6. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
7. MGT Capital Investments, Inc. Reports Fiscal 2008 Financial Results and Provides an Update on Recent Developments
8. IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification
9. Allscripts Reports Fiscal 2009 Third Quarter Results
10. J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members
11. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual ... City. He is known for his distinguished expertise and experience in the diagnosis and ... sub-specialty training in treating renovascular disease and aortic aneurysm . He is known ...
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
(Date:5/24/2017)... Las Vegas, NV (PRWEB) , ... May 24, ... ... Las Vegas, NV, recently completed Course II of the HP3 (High-Performance Periodontal Practice) ... commits himself to learning the latest advancements in his field by attending numerous ...
(Date:5/24/2017)... ... , ... If you are thinking of a visit to San Francisco , fall is ... perfect time to visit. , Business Architecture Associates is pleased to offer 5 days of ... a 4-½ day package for individuals, and as 4-½ day corporate package for up to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... label food ingredient solutions for the food and beverage industry offers Citri-Fi®, a ... ingredient statements during the purchasing decision process. As a result, labels need to ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology: